Cargando…

Clinically Relevant Insulin Degludec and Its Interaction with Polysaccharides: A Biophysical Examination

Protein polysaccharide complexes have been widely studied for multiple industrial applications and are popular due to their biocompatibility. Insulin degludec, an analogue of human insulin, exists as di-hexamer in pharmaceutical formulations and has the potential to form long multi-hexamers in physi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiwani, Shahwar Imran, Huang, Sha, Beji, Oritsegidenene, Gyasi-Antwi, Philemon, Gillis, Richard B., Adams, Gary G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077624/ https://www.ncbi.nlm.nih.gov/pubmed/32050432 http://dx.doi.org/10.3390/polym12020390

Ejemplares similares

Analysis of insulin glulisine at the molecular level by X-ray crystallography and biophysical techniques
por: Gillis, Richard B., et al.
Publicado: (2021)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Adams, Gary G., et al.
Publicado: (2017)

Isolation and Biophysical Characterisation of Bioactive Polysaccharides from Cucurbita Moschata (Butternut Squash)
por: Jiwani, Shahwar Imran, et al.
Publicado: (2020)

A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
por: Haahr, Hanne, et al.
Publicado: (2014)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
por: Kalra, Sanjay
Publicado: (2016)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

In-hospital experience with insulin degludec (IDeg)
por: Bulisani, Maria Gabriela Pedigoni, et al.
Publicado: (2015)

Pediatric diabetes: Potential for insulin degludec
por: Kalra, Sanjay, et al.
Publicado: (2014)

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Rapid quantification of insulin degludec by immunopurification combined with liquid chromatography high-resolution mass spectrometry
por: Reverter-Branchat, Gemma, et al.
Publicado: (2020)

Characterisation of insulin analogues therapeutically available to patients
por: Adams, Gary G., et al.
Publicado: (2018)

Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
por: Kiss, István, et al.
Publicado: (2013)

Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015)

Insulin Degludec Aspart: The First Co-formulation of Insulin Analogues
por: Kalra, Sanjay
Publicado: (2014)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

The Effectiveness of Lifestyle Adaptation for the Prevention of Prediabetes in Adults: A Systematic Review
por: Kerrison, George, et al.
Publicado: (2017)

Insulin Degludec: A Significant Advancement in Ultralong-Acting Basal Insulin
por: Kalra, Sanjay
Publicado: (2013)

Patient safety and minimizing risk with insulin administration – role of insulin degludec
por: Aye, Myint M, et al.
Publicado: (2014)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

SUN-179 Prolonged Hypoglycemia from Insulin Degludec
por: Kothari, Vallari, et al.
Publicado: (2019)

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec
por: Katakura, Yukino, et al.
Publicado: (2021)

Insulin degludec aspart: One-year real world experience
por: Kalra, Sanjay, et al.
Publicado: (2016)

Clinical use of Insulin Degludec: Practical Experience and Pragmatic Suggestions
por: Kalra, Sanjay, et al.
Publicado: (2015)

Insulin degludec in the first trimester of pregnancy: Report of two cases
por: Milluzzo, Agostino, et al.
Publicado: (2017)

Reduction of glycemic variability with Degludec insulin in patients with unstable diabetes
por: Henao-Carrillo, Diana Cristina, et al.
Publicado: (2018)

Successful Outcomes with Insulin Degludec in Pregnancy: A Case Series
por: Hiranput, Siwaporn, et al.
Publicado: (2018)

The Clinical Role of Insulin Degludec/Insulin Aspart in Type 2 Diabetes: An Empirical Perspective from Experience in Australia
por: Glastras, Sarah J., et al.
Publicado: (2020)

Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012)

Insulin degludec/insulin aspart combination for the treatment of type 1 and type 2 diabetes
por: Dardano, Angela, et al.
Publicado: (2014)

Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines
por: Mehta, Roopa, et al.
Publicado: (2020)

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
por: Nosek, Leszek, et al.
Publicado: (2014)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
por: Strain, W. David, et al.
Publicado: (2021)

Pregnancy outcomes in women with type 1 diabetes using insulin degludec
por: Ringholm, Lene, et al.
Publicado: (2022)

Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes
por: Home, P D, et al.
Publicado: (2012)

Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang, Fei, et al.
Publicado: (2012)

A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use
por: Haahr, Hanne, et al.
Publicado: (2016)

Pragmatic use of insulin degludec/insulin aspart co-formulation: A multinational consensus statement
por: Kalra, Sanjay, et al.
Publicado: (2016)

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
por: Buscemi, Silvio, et al.
Publicado: (2019)

A 1‐year, prospective, observational study of Japanese outpatients with type 1 and type 2 diabetes switching from insulin glargine or detemir to insulin degludec in basal–bolus insulin therapy (Kumamoto Insulin Degludec Observational study)
por: Shimoda, Seiya, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qnt7osuo199uugue0neqea3huc